M. Schell

Jacob G. Scott, M. Kattan, S. Eschrich, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

beta-Carotene treatment of cervical intraepithelial neoplasia: a phase II study.

M. Schell, S. Liao, Y. Peng, 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer

W. Fan, M. Schell, J. Fleming, 2022, Targeted Oncology.

Regular aspirin (ASA) use and survival in patients with PIK3CA-mutated metastatic colorectal cancer (CRC).

T. Yeatman, R. Jorissen, P. Gibbs, 2014 .

A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair pro ﬁ cient metastatic colorectal cancer

M. Schell, R. Mehta, Jun Zhou, 2021 .

A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).

M. Schell, O. Alese, Dae Won Kim, 2019, Journal of Clinical Oncology.

Autologous bone marrow transplant for children with AML in first complete remission: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse.

M. Schell, J. Ihle, R. Krance, 1991, Human gene therapy.

2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.

M. Schell, Raymond L. Blakley, V. Santana, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.

M. Schell, F. Harwood, Raymond L. Blakley, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer.

J. Pow-Sang, K. Egan, M. Schell, 2012, Contemporary clinical trials.

Influence of Serum and Tissue Micronutrient Levels on the Regression of Untreated Cervical Intraepithelial Neoplasia 2 and 3

B. Monk, M. Schell, K. Keefe, 2002, Journal of lower genital tract disease.

Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer.

M. Chambers, M. Schell, D. Brizel, 2014, Oral oncology.

T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma

M. Schell, Xuefeng Wang, S. Yoder, 2022, Journal for ImmunoTherapy of Cancer.

Preliminary Results of AML Therapy in Children Using Targeted Plasma Concentrations of Cytosine Arabinoside and Etoposide

M. Schell, R. Krance, C. Hurwitz, 1994 .

Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately High to Highly Emetogenic Chemotherapy: Comparison of Ondansetron, Prochlorperazine, and Dexamethasone

M. Socinski, M. Schell, C. Lindley, 2005, American journal of clinical oncology.

Childhood acute promyelocytic leukemia: a rare variant of nonlymphoid leukemia with distinctive clinical and biologic features.

M. Schell, G. Dahl, V. Santana, 1989, Leukemia.

Cutaneous Human Papillomaviruses and the Risk of Keratinocyte Carcinomas

V. Sondak, A. Giuliano, M. Schell, 2021, Cancer Research.

Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration.

W. Evans, M. Schell, W. Furman, 1995, Journal of pharmaceutical sciences.

A Randomized, Double Blind, Phase III Trial Using Oral β-Carotene Supplementation for Women with High-Grade Cervical Intraepithelial Neoplasia

H. Anton-Culver, M. Schell, S. Wilczynski, 2001 .

A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia.

H. Anton-Culver, M. Schell, S. Wilczynski, 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Myeloid-antigen expression in childhood acute lymphoblastic leukemia.

F. Behm, S. Raimondi, J. Shuster, 1991, The New England journal of medicine.

Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation

T. Yeatman, R. Jorissen, P. Gibbs, 2015, Acta oncologica.

Factors Associated with Postoperative Pulmonary Complications in Patients with Severe Chronic Obstructive Pulmonary Disease

M. Schell, S. Barker, D. Wong, 1995, Anesthesia and analgesia.

Therapy of Relapsed Acute Myeloid Leukemia Using Targeted Plasma Concentrations of Cytosine Arabinoside and Etoposide

M. Schell, J. Mirro, W. Crom, 1992 .

Visilizumab with Tacrolimus and Methotrexate for Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation From Mismatched Unrelated Donors

M. Schell, J. Pidala, C. Anasetti, 2016, Bone Marrow Transplantation.

BENEFICIAL EFFECT OF BRIEF PRE-TRANSFUSION INCUBATION OF PLATELETS AT 37°C

C. Pui, M. Schell, Winfred C. Wang, 1989, The Lancet.

Voriconazole Provides Effective Prophylaxis for Invasive Fungal Infection in Patients Receiving Glucocorticoid Therapy for Graft-Versus-Host Disease

M. Schell, J. Perkins, C. Anasetti, 2009, Bone Marrow Transplantation.

R C Millikan, M J Schell, R. Millikan, 2000, American journal of epidemiology.

Risk of breast cancer according to the status of HER-2/neu oncogene amplification.

R. Millikan, E. Liu, M. Schell, 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia.

F. Behm, S. Raimondi, M. Schell, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vivo percutaneous absorption of boric acid, borax, and disodium octaborate tetrahydrate in humans compared to in vitro absorption in human skin from infinite and finite doses.

H. Maibach, M. Schell, R. Wester, 1998, Toxicological sciences : an official journal of the Society of Toxicology.

Cutaneous Viral Infections Across 2 Anatomic Sites Among a Cohort of Patients Undergoing Skin Cancer Screening

A. Giuliano, M. Schell, J. Messina, 2018, The Journal of infectious diseases.

Cutaneous viral infections associated with ultraviolet radiation exposure

V. Sondak, A. Giuliano, M. Schell, 2020, International journal of cancer.

Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia.

F. Behm, S. Raimondi, C. Pui, 1990, Blood.

Tumour radiosensitivity is associated with immune activation in solid tumours.

S. Eschrich, J. Foekens, D. Coppola, 2017, European journal of cancer.

Immunohistochemical expression of neuron‐specific enolase and leu 7 in Ewing's sarcoma of bone

M. Schell, D. Parham, F. A. Hayes, 1989, Cancer.

The association of race/ethnicity, socioeconomic status, and physician recommendation for mammography: who gets the message about breast cancer screening?

M. Schell, S. Hawley, J. Earp, 2001, American journal of public health.

Epstein‐Barr virus latent membrane protein 1 induces the matrix metalloproteinase‐1 promoter via an Ets binding site formed by a single nucleotide polymorphism: Enhanced susceptibility to nasopharyngeal carcinoma

M. Schell, S. Kondo, T. Yoshizaki, 2005, International journal of cancer.

A phase II study of RO4929097 in metastatic colorectal cancer.

T. Yeatman, D. Coppola, M. Schell, 2012, European journal of cancer.

APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes

Lance T. Pflieger, T. Yeatman, M. Schell, 2021, Cancers.

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC

Timothy J. Yeatman, Michael J. Schell, Jamie K. Teer, 2016, Nature Communications.

Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic features

F. Behm, S. Raimondi, C. Pui, 1992 .

12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?

V. Sondak, S. Eschrich, M. Schell, 2012, Scientific Reports.

leukemia with hyperleukocytosis Complications and outcome in childhood acute lymphoblastic

M. Schell, G. Rivera, W. Crist, 2011 .

Complications and outcome in childhood acute lymphoblastic leukemia with hyperleukocytosis.

M. Schell, G. Rivera, W. Crist, 1992, Blood.

Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic features.

F. Behm, S. Raimondi, C. Pui, 1992, Blood.

Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse.

S. Raimondi, C. Pui, M. Schell, 1991, Blood.

vascular endothelial cells in vitro Nicotine stimulates DNA synthesis and proliferation in

A. Villablanca, D. Coppola, J. Cooke, 2015 .

Relationship of gliomas to the ventricular walls

Andrew E. Sloan, Michael J. Schell, Steven Brem, 2009, Journal of Clinical Neuroscience.

The false discovery rate: a key concept in large-scale genetic studies.

Michael J Schell, James J. Chen, P. Roberson, 2010, Cancer control : journal of the Moffitt Cancer Center.

ID1 Facilitates the Growth and Metastasis of Non-Small Cell Lung Cancer in Response to Nicotinic Acetylcholine Receptor and Epidermal Growth Factor Receptor Signaling

G. Bepler, D. Coppola, M. Schell, 2011, Molecular and Cellular Biology.

Vertebral compression fracture as a presenting feature of acute lymphoblastic leukemia in children

C. Pui, M. Schell, R. Ribeiro, 1988, Cancer.

Ectopic Expression of the Proto-oncogene Mer in Pediatric T-Cell Acute Lymphoblastic Leukemia

H. Snodgrass, M. Schell, J. Kurtzberg, 2006, Clinical Cancer Research.

An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy

Lance T. Pflieger, T. Yeatman, M. Schell, 2022, BMC cancer.

Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapse

S. Gruber, G. Rennert, C. Amos, 2021, Oncoimmunology.

Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations

T. Yeatman, M. Schell, A. Loboda, 2019, Cancer Epidemiology, Biomarkers & Prevention.

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

Eric B Haura, Bhupendra Rawal, Michael J Schell, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

M. Schell, G. Gibney, J. Weber, 2016, Cancer Immunology Research.

Adjusted odds ratios under nondifferential misclassification: application to prostate cancer.

M. Schell, P. Godley, 1999, Journal of clinical epidemiology.

Features of Potentially Predictive Biomarkers of Chemotherapeutic Efficacy in Small Cell Lung Cancer

G. Bepler, M. Schell, B. Rawal, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Determination of the number of observers needed to evaluate a subjective test and its application in two PD‐L1 studies

D. Rimm, M. Schell, Emily S. Reisenbichler, 2021, Statistics in medicine.

Empirically-derived synthetic populations to mitigate small sample sizes

Steven Eschrich, Michael J Schell, Anders Berglund, 2020, J. Biomed. Informatics.

Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing

T. Yeatman, M. Schell, D. Shibata, 2014, Journal of Clinical Pathology.

Suicide in patients with pancreatic cancer

M. Schell, P. Jacobsen, M. Malafa, 2011, Cancer.

ABCG2 expression, function, and promoter methylation in human multiple myeloma.

M. Schell, W. Dalton, P. Munster, 2006, Blood.

Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma

M. Schell, J. Fleming, M. Malafa, 2020, BMC Cancer.

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors

G. Bepler, M. Schell, S. Altiok, 2014, Clinical Cancer Research.

Steroid 5α-Reductase Isozymes I and II in Recurrent Prostate Cancer

M. Schell, J. Mohler, S. Maygarden, 2005, Clinical Cancer Research.

A Phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).

M. Schell, B. El-Rayes, O. Alese, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Integrative Analysis Identifies Multi-Omics Signatures That Drive Molecular Classification of Uveal Melanoma

G. Peng, M. Schell, H. Jim, 2021, Cancers.

Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells

G. Bepler, M. Schell, Jingchun Gao, 2009, Cancer biology & therapy.

Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status.

M. Socinski, M. Schell, T. Stinchcombe, 2006, Lung cancer.

Second-line gemcitabine in refractory stage IV non small-cell lung cancer: a phase II trial.

M. Socinski, M. Schell, M. Tynan, 2000, Clinical lung cancer.

Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission.

C. Pui, A. Look, M. Schell, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

G. Bepler, M. Schell, S. Gadgeel, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma

Gang Han, Christopher Garrett, Michael J Schell, 2011, International journal of cancer.

Acute nonlymphoblastic leukemia in infants: clinical presentation and outcome.

C. Pui, M. Schell, G. Dahl, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 trial of docetaxel and gefitinib in the first‐line treatment of patients with advanced nonsmall‐cell lung cancer (NSCLC) who are 70 years of age or older

Eric B Haura, Michael J Schell, Rachna Kapoor, 2008, Cancer.

Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose‐escalating conformal thoracic radiation therapy in unresectable Stage IIIA/B nonsmall cell lung carcinoma

M. Socinski, F. Detterbeck, M. Schell, 2000 .

Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy

F. Behm, C. Pui, M. Schell, 1990 .

Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy.

F. Behm, C. Pui, M. Schell, 1990, Blood.

PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation

T. Yeatman, M. Schell, Mingli Yang, 2018, Scientific Reports.

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.

M. Schell, B. El-Rayes, B. Kim, 2020, JAMA oncology.

Dose‐escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma

M. Socinski, F. Detterbeck, M. Schell, 2001, Cancer.

Thoracotomy for pulmonary metastatic osteosarcoma. An analysis of prognostic indicators of survival

M. Schell, W. Meyer, C. Pratt, 1987, Cancer.

Long‐term follow‐up of parental adjustment following a child's death at home or hospital

R. Mulhern, M. Schell, B. Camitta, 1989, Cancer.

Adverse prognostic features in 251 children treated for acute myeloid leukemia.

C. Pui, M. Schell, W. Crist, 1993, Medical and pediatric oncology.

Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a five-drug regimen including etoposide.

F. Behm, M. Schell, G. Dahl, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk of Breast Cancer According to the Status of HER-2 / neu Oncogene Amplification 1

R. Millikan, E. Liu, M. Schell, 2000 .

Effect of ND:YAG laser irradiation and root planing on the root surface: structural and thermal effects.

M W Berns, M J Schell, M. Berns, 1995, Journal of periodontology.

A Population-Based Case-Control Study of Farming and Breast Cancer in North Carolina

R. Millikan, D. Savitz, M. Schell, 2000, Epidemiology.

A Prospective Single Arm Phase I/II Study: Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer.

M. Schell, K. Latifi, T. Dilling, 2020, International journal of radiation oncology, biology, physics.

A Predictive Risk Probability Approach for Microarray Data with Survival as an Endpoint

T. Yeatman, S. Eschrich, James J. Chen, 2008, Journal of biopharmaceutical statistics.

Improved survival modeling in cancer research using a reduced piecewise exponential approach

Gang Han, Jongphil Kim, Michael J Schell, 2014, Statistics in medicine.

Phase II Trial of a GM-CSF-producing and CD40L-expressing Bystander Cell Line Combined With an Allogeneic Tumor Cell–based Vaccine for Refractory Lung Adenocarcinoma

G. Bepler, M. Schell, E. Haura, 2013, Journal of immunotherapy.

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

C. Horak, M. Schell, G. Gibney, 2014, Clinical Cancer Research.

Adrenocortical carcinoma in children: a study of 40 cases.

M. Schell, R. Ribeiro, L. Lacerda, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects

M. Relling, W. Evans, M. Schell, 1991, Clinical pharmacology and therapeutics.

Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer.

M. Fishman, M. Schell, Jingsong Zhang, 2022, Clinical genitourinary cancer.

Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma.

Joaquim M Farinhas, P. Stephens, D. Shin, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Continuous Toxicity Monitoring in Phase II Trials in Oncology

M. Schell, B. Qaqish, A. Ivanova, 2005, Biometrics.

Completion of adjuvant therapy in patients with resected pancreatic cancer.

M. Schell, J. Fleming, M. Malafa, 2020, HPB : the official journal of the International Hepato Pancreato Biliary Association.

ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.

Zhong Zheng, Elisabeth Brambilla, Michael J Schell, 2011, The American journal of pathology.

Circulating Immunosuppressive Regulatory T Cells Predict Risk of Incident Cutaneous Squamous Cell Carcinoma

M. Schell, J. Messina, D. Adeegbe, 2021, Frontiers in Medicine.

Identifying risk factors using a skin cancer screening program.

V. Sondak, M. Schell, J. Messina, 2013, Cancer control : journal of the Moffitt Cancer Center.

Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization

M. Schell, J. Perkins, J. Pidala, 2013, Bone Marrow Transplantation.

Effect of Age on Clinical Outcomes in Phase 1 Trial Participants.

M. Schell, B. Djulbegovic, D. Sullivan, 2015, Cancer control : journal of the Moffitt Cancer Center.

A Randomized, Controlled Trial of Graft-Versus-Host Disease (GVHD) Prophylaxis Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate: Analysis of GVHD, Relapse and Survival

M. Schell, J. Perkins, Jongphil Kim, 2009 .

Association of aspirin use with improved 5-year survival in colorectal cancer patients with PIK3CA mutation.

T. Yeatman, M. Schell, K. Fisher, 2013 .

Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.

C. Obasaju, G. Bepler, M. Schell, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers

G. Bepler, M. Schell, S. Altiok, 2013, Cancer.

Thymidylate synthase in situ protein expression and survival in stage I nonsmall‐cell lung cancer

G. Bepler, M. Schell, D. Boulware, 2008, Cancer.

A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer

M. Schell, R. Mehta, J. Strosberg, 2021, British Journal of Cancer.

Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer.

M. Socinski, M. Schell, D. Garfield, 2003, Lung cancer.

Second‐line, low‐dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first‐line chemotherapy with carboplatin plus paclitaxel

M. Socinski, A. Peterman, M. Schell, 2002, Cancer.

In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy

G. Bepler, A. Monteiro, M. Schell, 2009, Cancer investigation.

Chemoprevention Trial Feasibility Using Botanicals in Exceptionally High Risk Populations for Lung Cancer.

S. Sutton, M. Schell, E. Haura, 2014, Journal of clinical trials.

Serum CD4, CD8, and interleukin-2 receptor levels in childhood acute myeloid leukemia.

C. Pui, M. Schell, W. Crist, 1991, Leukemia.

Influence of Mindfulness-Based Stress Reduction (MBSR) on Telomerase Activity in Women With Breast Cancer (BC)

C. Lengacher, M. Schell, H. Jim, 2014, Biological research for nursing.

The contributions of patient factors, physician delay, and tumor biology to the outcome of gastric cancer.

L. Hourani, M. Schell, A. Wile, 1993, The American surgeon.

Preliminary indication of survival benefit from ERCC1 and RRM1‐tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis

G. Bepler, M. Schell, E. Haura, 2012, Cancer.

Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer.

J. Pow-Sang, M. Schell, P. Spiess, 2017, Oncotarget.

Photodynamic destruction of endometrial tissue with topical 5-aminolevulinic acid in rats and rabbits.

M W Berns, B. Tromberg, M. Wyss, 1994, American journal of obstetrics and gynecology.

Co-Evolution of Somatic Variation in Primary and Metastatic Colorectal Cancer May Expand Biopsy Indications in the Molecular Era

T. Yeatman, M. Schell, D. Greenawalt, 2015, PloS one.

Small cell lung cancer in women: risk associated with smoking, prior respiratory disease, and occupation.

M. Schell, K. Osann, J. Lowery, 2000, Lung cancer.

Organochlorines and 8-Hydroxy-2′-Deoxyguanosine (8-OHdG) in Cancerous and Noncancerous Breast Tissue: Do the Data Support the Hypothesis That Oxidative DNA Damage Caused by Organochlorines Affects Breast Cancer?

M. Schell, M. Graham, E. Willman, 2001, Archives of environmental contamination and toxicology.

Baseline Immune Biomarkers as Predictors of MBSR(BC) Treatment Success in Off-Treatment Breast Cancer Patients

C. Lengacher, M. Schell, K. Kip, 2014, Biological research for nursing.

A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.

M. Schell, L. Kvols, J. Strosberg, 2012 .

Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer.

M. Socinski, M. Schell, T. Hensing, 2005, Lung cancer.

Reproducibility of reported farming activities and pesticide use among breast cancer cases and controls. A comparison of two modes of data collection.

D A Savitz, E J Duell, R C Millikan, 2001, Annals of epidemiology.

A Randomized, Double Blind, Phase III Trial Using Oral (cid:1) -Carotene Supplementation for Women with High-Grade Cervical Intraepithelial Neoplasia 1

H. Anton-Culver, M. Schell, S. Wilczynski, 2001 .

Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins

Jong Y. Park, J. Pow-Sang, H. Parnes, 2016, Oncotarget.

The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel

M. Socinski, A. Peterman, M. Schell, 2003, Cancer.

Comparison of three methods to increase knowledge about breast cancer and breast cancer screening in screening mammography patients.

E. Pisano, M. Schell, S. Sejpal, 2007, Academic radiology.

Evidence-based target recall rates for screening mammography.

Michael J Schell, Bahjat F Qaqish, Rebecca Smith-Bindman, 2007, Radiology.

Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention

Michael J. Schell, Ganna Chornokur, Mohamed Helal, 2015, Cancer Prevention Research.

Green tea extract for prevention of prostate cancer progression in patients on active surveillance

J. Pow-Sang, M. Schell, Nagi B. Kumar, 2018, Oncotarget.

Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test

Michael J Schell, M. Schell, Jongphil Kim, 2012, Statistics in biopharmaceutical research.

The Intention-to-Treat Principle for Clinical Trials

G. Koch, C. Gennings, M. Schell, 2001 .

Recall and detection rates in screening mammography

Michael J Schell, Diana L Miglioretti, D. Miglioretti, 2004, Cancer.

Carcinoembryonic antigen and carbohydrate 19‐9 antigen as markers for colorectal carcinoma in children and adolescents

M. Schell, I. Fleming, C. Pratt, 1992, Cancer.

Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures

J. Pow-Sang, K. Egan, M. Schell, 2012, Journal of clinical trials.

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer

J. Nieva, M. Schell, T. Owonikoko, 2016, The oncologist.

MTX clearance is more important for intermediate-risk ALL.

C. Pui, W. Evans, M. Schell, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Approximations to the powers of the likelihood ratio tests: the loop ordering and slippage alternatives

F. T. Wright, M. Schell, Bahadur Singh, 1995 .

Effect of freezing on the relative escape force of sperm as measured by a laser optical trap.

M W Berns, M J Schell, M. Berns, 1995, Fertility and sterility.

Oral gargle-tumor biopsy human papillomavirus (HPV) agreement and associated factors among oropharyngeal squamous cell carcinoma (OPSCC) cases.

A. Giuliano, C. Chung, M. Schell, 2019, Oral oncology.

Clinical Safety , CorrelativeMarkers , andClinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

C. Horak, M. Schell, G. Gibney, 2015 .

Prognostic and predictive values of APC and WNT pathway mutations in MSS colorectal cancers.

M. Schell, J. Teer, B. Yue, 2015 .

Reassessment of breast cancers missed during routine screening mammography: a community-based study.

M J Schell, R. Bird, B. Yankaskas, 2001, AJR. American journal of roentgenology.

Expression of CXCR4, E-Cadherin, Bcl-2, and Survivin in Merkel Cell Carcinoma: An Immunohistochemical Study Using a Tissue Microarray

V. Sondak, M. Schell, J. Messina, 2012, The American Journal of dermatopathology.

Factors predicting successful needle-localized breast biopsy.

E. Pisano, M. Schell, L. A. Dunlap, 2003, Academic radiology.

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance

M. Schell, E. Haura, S. Antonia, 2019, British Journal of Cancer.

Methylation of HPV16 and EPB41L3 in oral gargles and the detection of early and late oropharyngeal cancer

A. Giuliano, C. Chung, M. Schell, 2022, Cancer medicine.

Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial.

Dung-Tsa Chen, Eric B Haura, Fredrik Pettersson, 2019, Translational cancer research.

Validation of a model predicting enrollment status in a chemoprevention trial for breast cancer.

M. Schell, S. Vernon, V. Vogel, 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: A single center, single arm trial.

Jiqiang Yao, M. Fishman, M. Schell, 2019, Journal of Clinical Oncology.

Laser photothermolysis of single blood vessels in the chick chorioallantoic membrane (CAM)

Michael W. Berns, Thomas E. Milner, J. Stuart Nelson, 1994, Other Conferences.

Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival

B. Barlogie, M. Schell, V. Bolejack, 2011, Annals of Hematology.

A phase I trial of panobinostat with ipilimumab in advanced melanoma.

M. Schell, J. Markowitz, J. Weber, 2017 .

Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.

M. Schell, M. Brenner, V. Santana, 1992, Bone marrow transplantation.

Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer

M. Schell, A. Gangi, S. Hoffe, 2018, Journal of surgical oncology.

Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer

T. Yeatman, A. Madan, M. Schell, 2016, BMC Medical Genomics.

Techniques to produce and evaluate realistic multivariate synthetic data

J. Heine, S. Eschrich, M. Schell, 2021, bioRxiv.

High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease.

R. Mulhern, J. Langston, M. Schell, 1991, The Journal of pediatrics.

SARS-CoV-2 antibody response duration and neutralization following natural infection.

A. Giuliano, M. Schell, C. Cubitt, 2023, Journal of clinical virology plus.

Isochromosomes in Childhood Acute Lymphoblastic Leukemia: A Collaborative Study of 83 Cases

F. Behm, S. Raimondi, C. Pui, 1992 .

Pediatric nonrhabdomyosarcomas of the extremities. Influence of size, invasiveness, and grade on outcome.

M. Schell, I. Fleming, M. Hudson, 1991, Archives of surgery.

Dose Limiting Pulmonary Toxicity in a Phase I/II Study of Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for Patients with Stage III Unresectable Non-small Cell Lung Cancer.

M. Schell, K. Latifi, T. Dilling, 2023, International Journal of Radiation Oncology, Biology, Physics.

Decision-making when data and inferences are not conclusive: risk-benefit and acceptable regret approach.

Iztok Hozo, Benjamin Djulbegovic, Michael J Schell, 2008, Seminars in hematology.

Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI).

M. Schell, G. Gibney, J. Weber, 2015 .

Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention

J. Pow-Sang, H. Parnes, K. Egan, 2015, Cancer Prevention Research.

Molecular analysis-directed, international, phase III trial in patients with advanced non-small-cell lung cancer.

G. Bepler, M. Schell, S. Gadgeel, 2013 .

Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.

D. Coppola, M. Schell, J. Strosberg, 2014, Endocrine-related cancer.

Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers

G. Bepler, M. Schell, S. Altiok, 2013, Cancer.

Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer.

J. Pow-Sang, K. Egan, M. Schell, 2012, Contemporary clinical trials.

Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in Non-Small Cell Lung Cancer.

M. Kattan, S. Eschrich, J. Torres-Roca, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.